Pharm

Tradipitant

search

Tradipitant, Nereus

  • See Also
  1. Motion Sickness
  2. Neurokinin-1 Receptor Antagonist
  • Indications
  1. Prevention of Motion-Induced Vomiting (Motion Sickness)
  • Mechanism
  1. See Neurokinin-1 Receptor Antagonist
  2. Tradipitant crosses the blood brain barrier to inhibit CNS Substance-P activity
    1. Reduces Motion-Induced Vomiting
  3. Blocks the neurokinin-1 receptor (NK1, a tachykinin)
    1. NK1 receptors are located in the ChemoreceptorTrigger Zone (Medulla Oblongata)
    2. Substance P normally binds NK1 to trigger Nausea and Vomiting
  • Dosing
  1. Tradipitant 85-170 mg orally 60 minutes before triggering event (e.g. boating)
  2. Take on an empty Stomach
  3. Do not repeat dosing for 24 hours
  • Efficacy
  1. Decreases Vomiting (NNT 4)
    1. However, minimal effect on motion-induced Nausea
  • Adverse Effects
  1. Expensive (in 2026, each 85 mg capsule retails for $255; direct to consumer price $85)
  2. Minimal sedation (contrast with Antihistamines such as Meclizine)
    1. However, manufacturer recommends avoiding driving after Tradipitant due to sedation risk
  • Safety
  1. Tradipitant is excreted in Breast Milk
    1. Observe nursing infant for Somnolence
  2. Unknown safety in pregnancy (not studied)
    1. However, no adverse effects in animal studies
  • Drug Interactions
  1. Strong CYP3A4 Inhibitors (e.g. Clarithromycin)
    1. Increases Tradipitant adverse effects (e.g. Somnolence)
  • Resources
  1. Tradipitant (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a021ebd-16ac-4354-b4b2-1c3950c091e5
  • References
  1. (2026) Presc Lett 33(6): 5-6
  2. Feng (2026) Am Fam Physician 114(1): 96-7 [PubMed]